Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency

R. Carter, A. Dirksen, E. Piitulainen, R. Stockley (United Kingdom; Hellerup, Denmark; Malmö, Sweden)

Source: Annual Congress 2010 - COPD: phenotyping and monitoring
Session: COPD: phenotyping and monitoring
Session type: Thematic Poster Session
Number: 1307
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Carter, A. Dirksen, E. Piitulainen, R. Stockley (United Kingdom; Hellerup, Denmark; Malmö, Sweden). Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency. Eur Respir J 2010; 36: Suppl. 54, 1307

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD)
Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases
Year: 2011


Severe alpha-1-antitrypsin deficiency (A1ATD) caused by Q0Ourém mutation: A clinical characterization
Source: Annual Congress 2010 - Genetics of obstruction
Year: 2010

Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD.
Source: Virtual Congress 2021 – COPD burden, epidemiology and management
Year: 2021


Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD).
Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases
Year: 2021


Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011


Erythrocyte abnormalities in alpha-1-antitrypsin deficiency (AATD) patients
Source: Annual Congress 2009 - COPD: exacerbation and clinical problems
Year: 2009

Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 501s
Year: 2003

Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease.
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019


Intra-epithelial polymerization, accumulation and secretion of alpha1 antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Epithelial cell biology
Year: 2010



Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough
Source: Eur Respir J 2016; 47: 35-38
Year: 2016


Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ)
Source: Eur Respir J 2006; 28: Suppl. 50, 144s
Year: 2006

Alpha 1 - antitrypsin deficiency: diagnosis and treatment
Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment
Year: 2021

Alpha-1-antitrypsin deficiency
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=139
Year: 2005

Characterization of a population of alpha1-antitrypsin deficient (A1ATD) patients
Source: Annual Congress 2008 - COPD
Year: 2008


Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years
Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD
Year: 2003


Occupational exposure in alpha-1-antitrypsin deficiency (AATD)
Source: Annual Congress 2008 - COPD and other environment-related lung diseases
Year: 2008

Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008


Short-term variability of biomakers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency
Source: Eur Respir J 2004; 24: Suppl. 48, 459s
Year: 2004

Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018